You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Safinamide mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for safinamide mesylate and what is the scope of freedom to operate?

Safinamide mesylate is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Prinston Inc, and Mdd Us, and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Safinamide mesylate has ninety-seven patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for safinamide mesylate
Anatomical Therapeutic Chemical (ATC) Classes for safinamide mesylate

US Patents and Regulatory Information for safinamide mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma SAFINAMIDE MESYLATE safinamide mesylate TABLET;ORAL 215902-002 Jun 14, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for safinamide mesylate

Country Patent Number Title Estimated Expiration
Poland 2474521 ⤷  Sign Up
Australia 2007263328 Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides ⤷  Sign Up
Israel 216403 הרכב רוקחי בתצורה משולבת המכיל סאלפינאמיד ואגוניסט דופמין ושימוש בו (Pharmaceutical composition in combined form comprising salfinamide and a dopamine agonist and uses thereof) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for safinamide mesylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1613296 92782 Luxembourg ⤷  Sign Up PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
1613296 132016000023012 Italy ⤷  Sign Up PRODUCT NAME: SAFINAMIDE(XADAGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/984, 20150224
1613296 15C0054 France ⤷  Sign Up PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.